On Apr. 21, 2020, Pharnext and the University Hospital Institute Mediterranee Infection in France, announced a new joint effort dedicated to researching potential drug candidates for fighting COVID-19 virus.

The joint activities will focus on rapidly testing in vitro a number of already approved drugs that were previously identified by Pharnext as potential candidates for fighting COVID-19 using its PLEOTHERAPY(TM) AI platform. The testing will include several high priority drug combination candidates against the COVID-19 virus, also identified by Pharnext using its PLEOTHERAPY(TM) AI platform.